Tezspire Achieves Landmark Phase III Success in Eosinophilic Esophagitis, Poised to Expand Blockbuster Legacy

London, UK – [Insert Current Date] – In a significant development for patients suffering from chronic inflammatory conditions, the co-developed blockbuster therapy Tezspire (tezepelumab) from Amgen and AstraZeneca has achieved a major Phase III clinical trial victory in eosinophilic esophagitis (EoE). This success marks a crucial step towards adding a third major indication to the drug’s rapidly expanding label, building upon its established efficacy in severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). The positive outcomes from the CROSSING trial (NCT05583227) suggest a promising new therapeutic avenue for individuals grappling with this debilitating esophageal disorder, further solidifying Tezspire’s position as a versatile and potent biologic targeting the upstream inflammatory pathway.

n

Main Facts: A New Horizon for Tezspire

n

Amgen and AstraZeneca’s innovative biologic, Tezspire, has reported overwhelmingly positive topline results from its pivotal Phase III CROSSING trial, demonstrating significant therapeutic potential for adult and adolescent patients with symptomatic and uncontrolled eosinophilic esophagitis. This groundbreaking win underscores Tezspire’s versatility as a first-in-class thymic stromal lymphopoietin (TSLP) blocker, which acts at the apex of the inflammatory cascade, making it uniquely positioned to address a spectrum of epithelial-driven inflammatory diseases.

n

The CROSSING trial meticulously evaluated the efficacy and safety of Tezspire in mitigating the severe symptoms of EoE, a chronic, immune-mediated inflammatory disease characterized by eosinophil infiltration of the esophagus, leading to impaired swallowing and other gastrointestinal distress. The study successfully met both of its co-primary endpoints:

n

n
1. Improved Swallowing Function: Patients receiving Tezspire experienced significantly greater ease of swallowing compared to those on placebo at week 24, an effect that was durably maintained through week 52. This outcome was assessed using a validated patient-reported measure, directly addressing one of the most burdensome symptoms of EoE.

n

2. Histologic Remission: A significantly higher proportion of patients treated with Tezspire achieved histologic remission, defined as an eosinophil count of six or fewer per high-power field (HPF) across multiple esophageal biopsies. This stringent criterion for remission highlights the drug’s profound impact on the underlying cellular inflammation driving EoE pathology.

n

n

The safety profile observed in the CROSSING trial was consistent with Tezspire’s established safety record in its currently approved indications, providing further confidence in its potential utility for a broader patient population. This Phase III triumph paves the way for regulatory submissions globally, offering renewed hope for the estimated hundreds of thousands of individuals worldwide living with uncontrolled EoE. The drug’s unique mechanism of action, targeting TSLP, positions it as a potentially critical addition to the therapeutic armamentarium, particularly for patients who may not adequately respond to existing treatments.

n

Chronology: Tezspire’s Journey and the Growing Need in EoE

n

The Genesis and Evolution of Tezspire

n

The story of Tezspire, or tezepelumab, began with a deep understanding of Type 2 inflammation, a complex immune response implicated in a host of allergic and inflammatory conditions. Tezepelumab is a human monoclonal antibody that targets and blocks thymic stromal lymphopoietin (TSLP), an epithelial-derived cytokine that acts as an "alarmin." TSLP plays a critical, upstream role in initiating and perpetuating Type 2 inflammation by activating various immune cells, including eosinophils, mast cells, and group 2 innate lymphoid cells (ILC2s). By blocking TSLP, Tezspire aims to interrupt the inflammatory cascade at its earliest stages, thereby preventing the release of downstream cytokines like IL-4, IL-5, and IL-13, which are key drivers of allergic inflammation.

n

The development journey saw Amgen and AstraZeneca forge a strategic collaboration, pooling their scientific expertise and resources. This partnership has been instrumental in navigating the complex landscape of drug development and regulatory approvals.

n

n
• Severe Asthma: Tezspire first gained prominence for its efficacy in severe asthma. Its approval in the United States by the Food and Drug Administration (FDA) in December 2021 (and subsequently in other regions) was based on robust data from the PATHFINDER clinical trial program, most notably the NAVIGATOR Phase III trial. This trial demonstrated Tezspire’s ability to significantly reduce the annualised asthma exacerbation rate (AAER) across a broad patient population, irrespective of baseline eosinophil counts, distinguishing it from other biologics that often target specific eosinophilic phenotypes. This broad applicability solidified its role as a vital treatment option for patients with severe, uncontrolled asthma.

n

• Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): Building on its success in asthma, Tezspire expanded its reach into another Type 2 inflammatory condition: CRSwNP. The DESTINATION Phase III trial provided the pivotal evidence for this indication, showing that Tezspire significantly improved nasal polyp size, nasal obstruction, and sense of smell in patients with inadequately controlled CRSwNP. This approval further cemented Tezspire’s status as a versatile anti-inflammatory agent, capable of addressing multiple manifestations of Type 2 inflammation.

n

n

The decision to investigate Tezspire in EoE was a natural progression, given the shared underlying mechanisms of epithelial-driven Type 2 inflammation across these conditions. The CROSSING trial, initiated to explore this potential, represented a strategic expansion of Tezspire’s therapeutic portfolio, aiming to leverage its upstream mechanism against yet another challenging inflammatory disease.

n

Understanding Eosinophilic Esophagitis (EoE)

n

Eosinophilic esophagitis is a chronic, immune-mediated disease characterized by inflammation of the esophagus, primarily driven by the infiltration of eosinophils. First recognized as a distinct clinical entity in the early 1990s, its prevalence has been steadily increasing worldwide, making it a growing public health concern. Affecting both children and adults, EoE is estimated to impact approximately 1 in 2,000 individuals, though diagnosis rates may still underestimate its true incidence due to its often subtle and varied presentation.

n

The disease manifests with a range of debilitating symptoms that significantly impair a patient’s quality of life. In adults, the most common symptoms include dysphagia (difficulty swallowing), food impaction (food getting stuck in the esophagus), chest pain, and heartburn that is unresponsive to standard acid-suppressive therapies. Children may present with feeding difficulties, poor weight gain, vomiting, and abdominal pain. The chronic inflammation leads to structural changes in the esophagus, such as strictures (narrowing), rings, and furrows, which further exacerbate swallowing difficulties and increase the risk of complications.

n

The diagnosis of EoE relies on a combination of clinical symptoms and endoscopic findings with esophageal biopsies. Endoscopy typically reveals characteristic features like rings, furrows, exudates (white spots), and strictures. The definitive diagnostic criterion is the presence of at least 15 eosinophils per HPF in one or more esophageal biopsies, after excluding other causes of esophageal eosinophilia, particularly gastroesophageal reflux disease (GERD).

n

Historically, the management of EoE has involved several approaches:

n

n
• Dietary Therapy: Elimination diets, often targeting common food allergens like dairy, wheat, soy, egg, nuts, and fish, can be highly effective but are challenging to adhere to and require careful nutritional monitoring.

n

• Proton Pump Inhibitors (PPIs): While primarily used for acid suppression, a subset of EoE patients (termed PPI-responsive esophageal eosinophilia) respond to high-dose PPIs, suggesting a role for acid in exacerbating inflammation or a distinct EoE phenotype.

n

• Topical Corticosteroids: Swallowed corticosteroids, such as fluticasone propionate (often inhaled and then swallowed) or budesonide oral suspension (like Takeda’s Eohilia, approved in early 2024), are considered the mainstay of pharmacologic treatment. These therapies work by locally suppressing inflammation in the esophagus.

n

• Biologics: Until recently, Dupixent (dupilumab), an IL-4/IL-13 blocker developed by Sanofi and Regeneron, was the only biologic approved for EoE, having received FDA approval in May 2022. Dupixent targets key cytokines involved in Type 2 inflammation, offering a systemic approach for patients unresponsive to or intolerant of other treatments.

n

n

Despite these options, a significant unmet need persists for many patients, particularly those with refractory disease or those seeking more convenient and durable treatment options. Tezspire’s entry into this landscape, with its distinct mechanism of action, offers the potential to address these gaps.

Supporting Data: Unpacking the CROSSING Trial Results

Deep Dive into the CROSSING Trial Results

The CROSSING trial (NCT05583227) was a meticulously designed Phase III, randomized, double-blind, placebo-controlled study aimed at evaluating the efficacy and safety of Tezspire in a challenging patient population: adults and adolescents (aged 12-17 years) with symptomatic and uncontrolled EoE. The trial design incorporated rigorous assessment methods to capture both symptomatic improvement and histological resolution of inflammation, ensuring a comprehensive understanding of Tezspire’s impact.

The co-primary endpoints were strategically chosen to reflect the most pressing concerns for EoE patients and clinicians:

• Dysphagia Symptom Questionnaire (DSQ) Score: This patient-reported outcome measure is a widely accepted and validated tool for quantifying the severity and frequency of swallowing difficulties. The significant improvement observed in DSQ scores at week 24, and its sustained effect through week 52, directly translates to a meaningful reduction in a patient’s daily burden. This objective improvement in a subjective symptom is paramount for enhancing quality of life for individuals who often face social isolation and anxiety related to eating. The magnitude of the improvement, though not yet specified in exact figures in the topline readout, was deemed "significant," implying a clinically relevant difference from placebo.
• Histologic Remission: Achieving histologic remission is a critical objective in EoE treatment, as it signifies control over the underlying inflammatory process and is associated with a reduced risk of long-term complications like esophageal strictures. The trial’s definition of histologic remission as ≤6 eosinophils per HPF is notably stringent. As highlighted by a systematic review published in JGH Open, there’s considerable variability in the thresholds used to define remission in EoE studies, with some accepting higher counts. By setting a lower bar for success, Amgen and AstraZeneca have demonstrated Tezspire’s robust ability to clear eosinophilic inflammation from the esophageal lining. The statistically significant proportion of patients achieving this rigorous endpoint underscores the drug’s potent anti-inflammatory effects.

While the topline readout focused on the co-primary endpoints, it is highly probable that the detailed data to be presented at an upcoming medical conference will include a wealth of secondary endpoint analyses. These might encompass:

• Endoscopic Improvement: Changes in endoscopic severity scores (e.g., EREFS score) reflecting improvements in features like edema, rings, exudates, furrows, and strictures.
• Quality of Life Measures: Assessment of disease-specific and generic quality of life instruments to capture the broader impact of treatment on patients’ well-being.
• Other Inflammatory Markers: Changes in blood eosinophil counts, serum IgE levels, or other biomarkers of Type 2 inflammation, which could further elucidate Tezspire’s systemic effects.
• Long-term Safety and Efficacy: The 52-week data on swallowing ease provides an initial look into durability, but longer-term follow-up would be crucial for understanding sustained benefits and safety.

The reported safety profile, "similar to its approved indications," is a reassuring finding. For Tezspire, this generally includes common adverse events such as nasopharyngitis, arthralgia, back pain, pharyngitis, and injection site reactions. The consistency of the safety profile across different indications suggests a predictable and manageable risk-benefit ratio for patients with EoE.

Tezspire’s Unique Mechanism of Action: The TSLP Advantage

Tezspire stands apart from many other biologics by targeting TSLP, a cytokine strategically positioned at the very beginning of the Type 2 inflammatory pathway. Often referred to as an "alarmin," TSLP is released by epithelial cells in response to various environmental insults, allergens, viruses, or tissue damage. Once released, TSLP acts as a crucial initiator of allergic inflammation by activating a wide array of immune cells, including dendritic cells, mast cells, basophils, and group 2 innate lymphoid cells (ILC2s). These activated cells then release a cascade of downstream Type 2 cytokines, such as interleukin-4 (IL-4), IL-5, and IL-13, which are directly responsible for recruiting eosinophils, promoting IgE production, and driving mucus hypersecretion and airway hyperresponsiveness characteristic of allergic diseases.

The key advantage of blocking TSLP is its upstream position. By intercepting the inflammatory signal at its origin, Tezspire has the potential to broadly suppress Type 2 inflammation, regardless of the specific downstream cytokine profiles or the patient’s individual biomarker levels (e.g., eosinophil count, IgE). This "pan-Type 2" effect differentiates it from biologics that target specific downstream cytokines, such as:

• IL-5 blockers (e.g., mepolizumab, reslizumab, benralizumab): Primarily effective in patients with high eosinophil counts.
• IL-4/IL-13 blockers (e.g., dupilumab): Block the signaling pathways of IL-4 and IL-13, which are central to allergic inflammation but are downstream of TSLP.

In the context of EoE, where Type 2 inflammation is a primary driver, Tezspire’s TSLP blockade offers a compelling therapeutic strategy. It directly addresses the epithelial dysfunction that is believed to initiate the inflammatory cascade in the esophagus, reducing the recruitment and activation of eosinophils, and potentially remodeling the esophageal tissue. This upstream intervention holds promise for a broader population of EoE patients, including those who may not fit neatly into specific endotypes or those who have had inadequate responses to other targeted therapies.

Official Responses: Confidence and Regulatory Momentum

Statements from Amgen and AstraZeneca

The positive outcome of the CROSSING trial has been met with significant enthusiasm from both Amgen and AstraZeneca, underscoring the collaborative success of their partnership and their shared commitment to advancing patient care in inflammatory diseases.

Jay Bradner, Amgen’s executive vice president of Research & Development, AI, and Data, articulated the profound impact of Tezspire’s findings: “In this Phase III trial, Tezspire improved both the underlying inflammation and the swallowing difficulties that can make EoE so disruptive for patients. That combination is important for patients and builds confidence in Tezspire as a potential new treatment for people struggling with EoE.” His statement highlights the dual benefit of Tezspire, addressing not only the symptomatic burden but also the core pathological mechanisms of the disease, a crucial factor for long-term management and patient well-being.

Adding to this sentiment, a representative from AstraZeneca, likely a senior executive in the Biopharmaceuticals R&D division, would likely echo this optimism, stating: “The success of Tezspire in EoE further validates our strategic focus on understanding and targeting fundamental inflammatory pathways. For patients with EoE, who often face significant challenges in their daily lives due to dysphagia and the constant threat of complications, these results represent a vital step forward. We are incredibly proud of this achievement and look forward to working closely with regulatory authorities to bring this important new option to those who need it most, further extending Tezspire’s legacy as a transformative medicine.” Such a statement would reinforce the strategic importance of Tezspire within AstraZeneca’s portfolio and its broader mission in respiratory and immunology.

The partnership between Amgen and AstraZeneca has been a cornerstone of Tezspire’s development and commercialization. This latest success in EoE serves as a testament to the power of such collaborations in accelerating the discovery and delivery of innovative medicines to patients with high unmet needs.

Regulatory Pathway and Future Presentations

Following the definitive positive outcome of the CROSSING trial, Amgen and AstraZeneca are poised to move swiftly towards regulatory submissions. The next critical steps involve:

• Regulatory Filings: The companies will compile and submit comprehensive data packages, including the full results from the CROSSING trial, to regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other health authorities worldwide. This typically involves filing a supplemental Biologics License Application (sBLA) in the U.S. and a Marketing Authorization Application (MAA) in Europe. Given the significant unmet need in EoE and the compelling nature of the data, these applications are likely to be granted priority review status in some regions, potentially accelerating the approval timeline.
• Medical Conference Presentations: A key aspect of disseminating groundbreaking clinical trial results is their presentation at major international medical conferences. Amgen and AstraZeneca have indicated they will share detailed data from the CROSSING study at an upcoming medical conference. This platform allows for peer review, expert discussion, and broad dissemination of the findings to the global medical community. Such conferences often include Digestive Disease Week (DDW), the American College of Gastroenterology (ACG) Annual Scientific Meeting, or United European Gastroenterology (UEG) Week, all prominent venues for gastroenterology research. These presentations are crucial for educating clinicians on the efficacy, safety, and optimal use of Tezspire in EoE.

The regulatory review process typically involves a thorough evaluation of the submitted data, including clinical efficacy, safety, and manufacturing information. If approved, Tezspire would significantly expand the therapeutic landscape for EoE, offering a new systemic treatment option that targets a fundamental upstream pathway of inflammation.

Implications: Reshaping the EoE Landscape and Tezspire’s Legacy

Impact on Patients with Eosinophilic Esophagitis

For patients living with eosinophilic esophagitis, the potential approval of Tezspire represents a beacon of hope. EoE is a chronic, often lifelong condition that profoundly impacts daily life. The constant fear of food impaction, the need for dietary restrictions, the discomfort of dysphagia, and the potential for esophageal damage can lead to significant psychological distress, social isolation, and a reduced quality of life.

The ability of Tezspire to not only improve swallowing difficulties but also to achieve stringent histologic remission offers a comprehensive solution. Patients could experience:

• Improved Quality of Life: Reduced dysphagia means easier, more comfortable eating, allowing for greater enjoyment of meals and less anxiety around food. This can lead to a significant improvement in social interactions and overall well-being.
• Reduced Need for Dietary Restrictions: While some patients may still require dietary modifications, effective medical treatment could potentially lessen the severity or number of restrictions, offering greater dietary freedom.
• Prevention of Complications: By controlling the underlying inflammation, Tezspire could help prevent the progression of esophageal damage, including the formation of strictures, which often require endoscopic dilations.
• A New Option for Non-Responders: For patients who have not achieved adequate control with dietary changes, PPIs, topical steroids, or even existing biologics like Dupixent, Tezspire’s distinct mechanism of action offers an alternative pathway to disease control. This is particularly crucial for the refractory patient population.

The introduction of Tezspire would empower patients and their healthcare providers with another powerful tool to manage a complex and challenging disease, moving closer to individualized treatment strategies based on a deeper understanding of each patient’s inflammatory profile.

Market Dynamics and Competitive Landscape

The EoE therapeutic market is dynamic and growing, driven by increasing disease awareness, improved diagnostic capabilities, and the availability of new treatments. Tezspire’s entry, if approved, will undoubtedly reshape the competitive landscape.

• Current Competitors: The primary competitors in the EoE biologic space are Sanofi and Regeneron’s Dupixent (dupilumab) and Takeda’s Eohilia (budesonide oral suspension).
  • Dupixent: As the first FDA-approved biologic for EoE, Dupixent has established a foothold. It targets the IL-4 and IL-13 pathways, which are critical Type 2 cytokines. Its efficacy has been well-demonstrated in reducing eosinophil counts and improving symptoms.
  • Eohilia: Approved in early 2024, Eohilia is a corticosteroid in an oral suspension formulation designed for local action in the esophagus. It offers a non-biologic, topical approach to inflammation control.
• Tezspire’s Differentiation: Tezspire’s unique selling proposition lies in its upstream TSLP blockade. This mechanism could offer advantages:
  • Broader Patient Population: By targeting TSLP, Tezspire may be effective in a wider range of EoE patients, including those with lower baseline eosinophil counts or those who do not respond adequately to IL-4/IL-13 blockade. This "pan-Type 2" effect could provide a more universal solution.
  • Mechanism Synergy/Complementarity: While Dupixent targets downstream cytokines, Tezspire acts earlier. This could lead to discussions about sequencing or even combination therapies in the future, although this is purely speculative at this stage.
  • Administration: Tezspire is administered as a subcutaneous injection, similar to Dupixent, offering convenience compared to daily oral suspensions for some patients.
• Market Forecasts: GlobalData analysts have already projected Tezspire to reach blockbuster status, generating $1.13 billion in revenue for AstraZeneca in 2025 based on its existing indications. The positive EoE data significantly bolsters its commercial outlook. GlobalData now forecasts peak sales of over $4 billion for Tezspire, primarily driven by its expanding indications across multiple epithelial-driven inflammatory disorders. This substantial increase reflects the large unmet need in EoE, the drug’s robust efficacy, and its differentiated mechanism of action. The Q2 2026 revenue uptick of 45% to $390 million already signals strong growth, and the addition of EoE will undoubtedly accelerate this trajectory.
• Future Competition: The pharmaceutical pipeline for EoE continues to evolve, with other investigational therapies exploring various targets, including mast cell stabilizers, JAK inhibitors, and other biologics. Tezspire will need to establish its efficacy and safety profile firmly to secure a leading position in this competitive and expanding market.

Strategic Vision for Amgen and AstraZeneca

The success of Tezspire in EoE is a cornerstone of Amgen and AstraZeneca’s strategic vision to expand the drug’s utility across a spectrum of epithelial inflammatory disorders. Both companies recognize the significant commercial and medical value of developing therapies that can address multiple related conditions.

• Reinforcing Blockbuster Status: With approvals in severe asthma, CRSwNP, and now strong data in EoE, Tezspire is firmly establishing its "blockbuster legacy." Each new indication not only adds revenue streams but also reinforces the drug’s scientific credibility and market presence.
• Broader Immunology Portfolio: Tezspire is a critical asset within both companies’ immunology and respiratory portfolios. Its success validates their investment in biologics targeting upstream inflammatory pathways, suggesting potential for further pipeline development in this area.
• Exploring Other Indications: The original article mentions chronic obstructive pulmonary disease (COPD) as another potential indication being explored. This highlights a deliberate strategy to identify and pursue conditions where TSLP plays a significant pathophysiological role, thereby maximizing the drug’s impact and commercial potential. The success in EoE, an eosinophil-driven disease, strengthens the rationale for exploring other eosinophilic or Type 2 inflammatory phenotypes within broader diseases like COPD.
• Precision Medicine: The ability of Tezspire to act broadly on Type 2 inflammation, irrespective of specific biomarkers like eosinophil counts, aligns with a broader trend in precision medicine where therapies are increasingly tailored to underlying biological mechanisms rather than just symptomatic presentations.

In conclusion, Tezspire’s Phase III victory in eosinophilic esophagitis marks a pivotal moment for both Amgen and AstraZeneca, and more importantly, for patients living with this challenging disease. The compelling data on improved swallowing and histologic remission, coupled with a consistent safety profile, positions Tezspire as a strong contender for a significant role in the EoE treatment paradigm. As regulatory submissions progress and detailed data become public, the medical community eagerly awaits the full implications of this breakthrough, anticipating a new era of effective management for eosinophilic esophagitis and a further cementing of Tezspire’s burgeoning blockbuster legacy.